ArticleBMC cancer2026
Blood circulating C228T TERT gene promoter mutation is an independent factor for the prognosis of HBV-related hepatocellular carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTelomerase reverse transcriptase (TERT) promoter mutations are among the most common noncoding genetic lesions in various cancers, including hepatocellular carcinoma (HCC). The clinical and pathological implications of hepatitis B virus (HBV)-related HCC patients carrying promoter mutations are only partially resolved.
methodsA nested real-time PCR assay was optimized to detect C228T TERT gene promoter mutation (C228T) from plasma samples with a detection limit of 0.1%. The established assay was used to investigate the association of the C228T with the clinical presentation of HBV-related HCC patients.
resultsThe C228T was detected only in the HCC group (n = 40/159, 25.2%), not in the other control groups (n = 0/160). The mutation rate was significantly higher in HCC patients with low albumin concentration, increased direct bilirubin, abdominal lymphadenopathy, and portal vein thrombosis, compared with HCC patients without these factors (p < 0.05); the mutation rate also increased progressively with more advanced stages (p < 0.05) and was significantly associated with shorter overall survival (OS).
conclusionThe C228T is associated with advanced stages, poorer liver function, and shorter overall survival; hence, it could be used as a novel biomarker for the prognosis of HBV-related HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.